SCHEMBL24365040

SCHEMBL24365040

C1=C(c2csc3ccccc23)NCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM5 P08912 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ HPGD P15428 3/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ CYP2A6 P11509 3/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC10 Q969S8 1/20 0.34
▸ HDAC11 Q96DB2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4381193 0.71 CYP2A6 (0.54) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL24365752 0.70 NAMPT (0.35) ALDH1A1
SCHEMBL31358125 0.69 HTR2A (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3
Hydrochloric Acid SCHEMBL31358068 0.68 HTR2A (0.44) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL10017087 0.66 NISCH (0.42) HPGDALDH1A1MAPT
SCHEMBL4359561 0.66 HTR2C (0.54) HTTALDH1A1MAPT
SCHEMBL31390342 0.65 NPC1 (0.47) HPGDLMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL23555986 0.64 ERN1 (0.54) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL31092063 0.64 CYP2A6 (0.52) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL5848721 0.64 CYP2A6 (0.52) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 CHRM2 13/4885CHRM4 138/4885CHRM5 45/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 CHRM2 13/4885CHRM4 138/4885CHRM5 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback